

Learning Objectives

After completing this activity, the participant should be better able to:

- Describe the multiple myeloma (MM) disease definitions and diagnostic criteria based on IMWG guidelines
- Outline the classification and risk stratification on MM and smoldering MM
- Identify and select ASCT and/or AST in transplantation eligible patients with newly diagnosed MM
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active MM
- Customize the use of maintenance therapy approaches in the post-transplant and non-transplant settings based on patient- and disease related factors including cytogenetic profile
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Describe the natural history of precursor disorder, either smoldering myeloma or MGUS and see whether disease state can be altered by treating earlier to avoid progression to MM
- Assess the ongoing clinical trials investigating the innovative approaches for MM and refer patients for study participation.